ANGLE reveals key potential uses of its liquid biopsy tackling head and neck cancer
Global biopsy company, , said on Friday that a recent study with the University of Birmingham has outlined some “key benefits” of the company’s Parsortix® system addressing treatment for cancer of the neck and head.
The study entailed a review of research into the use of circulating tumor cell markers used to treat the strain of cancer specific to the neck and head which is the sixth most common cancer worldwide.
In total, some 650,000 of new patients are diagnosed annually resulting in more than 350,000 deaths every year.
The review pinpointed key potential uses of a CTC liquid biopsy over traditional tissue biopsies as more beneficial -- the ability to repeat an investigation at multiple time points, for instance, alongside a reduction in overall healthcare costs.
Most notably, the published results identified advantages of the Parsortix system over other CTC liquid biopsy systems which have proven to hold “significant limitations” in this indication.
Specifically, what makes ANGLE’s system more favourable is a system which is not antibody-dependent and is able to detect all sub-populations of CTCs as well as CTC clusters, the review explained.
One major opportunity identified by the review is the need to detect, by way of investigation of the harvested CTCs, whether the cancer is PD-L1 (programmed death-ligand 1) positive -- PD-L1 being a potential biomarker for immunotherapy, which may indicate likely response to immunotherapy drugs.
Currently, ANGLE has said they are continuing its processes for the investigation of CTCs to determine the presence or absence of this PD-L1 expression -- the firm has characterised their development as “already well advanced”.
ANGLE Founder and Chief Executive, Andrew Newland, commented, "This review of current research clearly identifies the potential for using CTC liquid biopsies to improve treatment of head and neck cancer."
Mr Newland added, “We are pleased that key advantages of ANGLE's Parsortix system have been recognised and believe that head and neck cancer is another opportunity for ANGLE, once we have our own clinical laboratory established."
For More News and Updates on ANGLE plc:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.